Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 16, 2018

Primary Completion Date

March 3, 2023

Study Completion Date

September 3, 2023

Conditions
STEMIChest Pain
Interventions
PROCEDURE

percutaneous intervention (PCI)

Successful PCI with the patent vessel and at least Thrombolysis in Myocardial Infarction (TIMI) 2 flow in the left anterior descending artery (LAD) post-PCI.

DRUG

Microbubbles

The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.

PROCEDURE

Ultrasound

Intermittent high Mechanical Index (MI) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MegaHertz (MHz); pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area

Trial Locations (2)

Unknown

University of Sao Paulo Medical Center, São Paulo

VU University Medical Center, Amsterdam

All Listed Sponsors
collaborator

InCor Heart Institute

OTHER

collaborator

VU University of Amsterdam

OTHER

lead

University of Nebraska

OTHER

NCT02170103 - Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial | Biotech Hunter | Biotech Hunter